Recombinant Antibody Expression is a crucial step in developing therapeutic antibodies, encompassing processes such as screening for high-affinity antibodies and humanized antibodies, large-scale antibody production, and downstream functional validation. It is also a critical technology for the industrialization of monoclonal antibody drugs. Furthermore, monoclonal hybridoma cell lines generated via hybridoma technology are subject to loss of high-quality monoclonal antibodies due to factors like cell contamination or improper cell line preservation. Recombinant Antibody Expression resolves this issue. We only need to sequence the hybridoma cells to obtain the monoclonal antibody gene sequence and then produce the required antibody through recombinant expression.  Recombinant antibodies are widely used in areas including immunodiagnostics, ELISA kit development, immunological detection, biomarker identification, and therapeutic antibody development.

Figure 1 Phage Display Combined with Mammalian-expressed Humanized Rabbit IgG

KMD Bioscience has established a comprehensive Recombinant Antibody Preparation and Production System based on its mature Protein Expression Platform. It possesses multiple expression systems suitable for antibody production, including: Prokaryotic Expression Systems (including but not limited to hosts such as E.coli BL21, Nissle 1917, E.coli Rosetta), Mammalian Expression Systems (including but not limited to hosts such as Expi 293F, Freestyle 293F, CHO-S, CHO-K1, 293T), Yeast Expression Systems (including but not limited to Pichia pastoris Expression Systems and Saccharomyces cerevisiae Expression System such as GS115 and X33). For each expression system, KMD Bioscience has developed its own proprietary soluble high-expression vectors. This enables the provision of recombinant antibody preparation services for a wide range of formats, including but not limited to VHH, scFv, Fab, antibodies from various species (including but not limited to human, murine, rabbit, as well as chimeric and humanized antibodies), various IgG subtypes (including IgG1, IgG2, IgG3, IgG4), and various types of antibody fusion proteins (including single-chain antibody fusion proteins, VHH fusion proteins, etc.). Leveraging our GMP/GLP Fermentation Platform and systems of various scales (including but not limited to 5L, 10L, 30L, 80L, 130L, and 250L fermentation systems), KMD Bioscience is capable of providing high-quality Recombinant Antibody Expression Services at different production yields, with the maximum yield reaching up to 5g/L.

KMD Bioscience provides One-Stop Recombinant Antibody Expression Services encompassing sequence analysis (including transmembrane and hydrophilicity analysis), tag design (including but not limited to affinity tags, solubilizing tags, and biotinylated tags), linker design, vector construction, recombinant antibody expression and purification.  Additionally, KMD Bioscience offers comprehensive downstream testing and validation, including antibody labeling, affinity measurement, ELISA validation, flow cytometry validation, immunological detection, and therapeutic antibody screening.  Clients simply provide the antibody sequence and project requirements.  KMD Bioscience scientists are capable of designing customized project plans and delivering technical support for research objectives.